EORTC shared a post on LinkedIn:
“New trial alert!
We’re launching the EORTC-2334-BTG LUMEN-1 clinical trial to explore [177Lu] Lu-DOTATATE as a new treatment for recurrent meningioma. This trial will investigate the effectiveness of this new treatment in targeting a specific receptor found in most meningiomas.
It involves 136 patients across 35 sites in 10 European countries, aiming to improve progression-free survival and quality of life.
Learn more about the LUMEN-1 trial.”